The company?s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity of VAL-083 in patients with glioblastoma multiforme, a form of brain cancer. DelMar Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.